Destiny Pharma announces positive interim safety review of its ongoing Phase IIb study of antibiotic XF-73 nasal gel for prevention of post-surgical Staphylococcal infections

An Independent Data Monitoring Committee has now reviewed safety data from the first 75 cardiac surgery patients who have completed study treatment and found no concerning safety issues. Recruitment to study is expected to be completed by the end of 2020.